Production (Stage)
Elite Pharmaceuticals, Inc.
ELTP
$0.517
-$0.0022-0.42%
OTC PK
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 256.06% | 1.31% | -1,892.17% | -81.48% | 370.82% |
| Total Depreciation and Amortization | 6.31% | -11.54% | -0.93% | 11.56% | 42.88% |
| Total Amortization of Deferred Charges | 0.00% | 0.00% | 0.00% | -- | -- |
| Total Other Non-Cash Items | -135.42% | -16.08% | 388.05% | 172.61% | -214.92% |
| Change in Net Operating Assets | -263.95% | -14.05% | -139.87% | -141.35% | 132.88% |
| Cash from Operations | 468.34% | -173.02% | -53.67% | 49.77% | 187.89% |
| Capital Expenditure | -- | 100.00% | 88.13% | -92.89% | 0.59% |
| Sale of Property, Plant, and Equipment | -- | -100.00% | 618.95% | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | 100.00% | -- | -- |
| Cash from Investing | -- | -100.00% | 101.06% | -312.12% | 0.59% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | 19.06% | 39.79% | -83.36% | 56.38% | -966.49% |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 29.05% | 39.79% | -83.36% | 56.38% | -966.49% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 340.84% | -208.94% | -11.68% | 0.88% | 145.72% |